However, c10orf118 silencing modified the expression of HAS2 and its epigenetic regulator HAS2-AS1 [37,38], as well as the levels of the HA receptor CD44, suggesting a specific effect on HA metabolizing genes rather than the behaviour of breast cancer cells. The gene discussed is HAS2; the disease is breast carcinoma.